To date, Imitrex is the first-line drug in the treatment of migraine attacks. To quickly get rid of a headache, you should buy Imitrex and begin using it as soon as possible after the onset of a migraine attack. However, the medicine is equally effective at any stage of the attack.
The clinical effect of Imitrex develops:
- 10 minutes after subcutaneous injection.
- 15 minutes after intranasal administration.
- 30 minutes after oral administration.
Today,Imitrex has the largest evidence base in the treatment of migraine attacks among all anti-migraine drugs. In clinical practice, the drug is used to quickly and effectively arrest the attacks of headache.
To quickly get rid of the headache, patient can use one of three dosage forms of Imitrex:
- tablets of 25 mg, 50 mgand 100 mg
- nasal spray of 5mg, 10 mgand 20 mg
- injection solution 8 mg/ml and 12 mg/ml
The high cost of Imitrex in a conventional pharmacy limits its use and the commitment of patients to headache therapy. To save money, patients can buy Imitrex online at a reduced price.
The dosage of Imitrex, sufficient to relieve acute migraine attacks, is:
- tablets: 50mg -100 mg once, with the possibility of additional dosing 2 hours after the first intake;
- subcutaneous injections: 1mg -6 mg once, with a possibility to administer another dose 1 hour after the first injection;
- nasal spray: 5-20 once,and another dose 2 hours after the first spray, if necessary.
Imitrex tablets should be swallowed whole with plenty of water. Subcutaneous injections are performedwith an autoinjector. Advantages of intranasal Imitrex administration are the rapid onset of action and high systemic absorption of the active ingredient Sumatriptan through the nasal mucosa.
Nausea and vomiting, often associated with a migraine attack, significantly reduce the therapeutic effect of Imitrex tablets. Subcutaneous or intranasal administration of the drug is an affordable, effective and safe treatment for a migraine, which is accompanied with nausea and vomiting.
Imitrex is the first trademark of Sumatriptan. The drug was synthesized in 1989 under the leadership of Patrick Humphrey and his colleagues from the pharmaceutical company GlaxoSmithKline. Sumatriptan was much more effective than the anti-migraine drug Ergotamine that was mainly used back then, and did not cause any significant side effects.
Imitrex has made a revolutionary breakthrough in the treatment of headache attacks, bringing many patients a significant relief from migraines. Despite the fact that about 30 years have passed since the introduction of the drug into clinical practice, many patients still buy Imitrex and use it to relieve the headache.
Almost immediately after the development,Imitrex became the gold standard of migraines treatment in many countries of the world. In the USA, the drug was registered on December 28, 1992. According to statistics, total sales of Imitrexby 2007 exceeded $ 1.12 billion, making it the best-selling antimigraine drug in the world.
In February 2009, the term of Imitrex patent protection expired. Pharmaceutical companies were given the opportunity to register their own trademarks for Sumatriptan, as well as to produce a drug under a generic name.
Currently, Americans can use Imitrex to stop migraine attacks. In pharmacies, Sumatriptan is sold under other trademarks – Alsuma, Onzetra, Sumavel, Zembrace, as well as under its own non-proprietary name.
At present, Imitrex and its generics remain the only effective and safest drugs for the management of acute migraine attacks. Patients, who do not respond to other drugs for headache (NSAID, opioid analgesics), can buy Imitrex and use it for migraine treatment.